Here below are the publications (3) participated by Francesco Bertoni using the term string bet (as cross-checked throughout PubMed, counted from 2020, including only Ticino affiliations).
Any wrong or incomplete data? Any missing, misplaced, unlicensed picture? Please report any abuse, inaccuracy or lack of information to info@ticinoscienza.ch

1) Pharmacologic screen identifies active combinations with BET inhibitors and LRRK2 as a novel putative target in lymphoma
eJHaem, 27 luglio 2022

2) Antitumor activity of the dual BET and CBP/EP300 inhibitor NEO2734
Blood Advances, https://ashpublications.org/bloodadvances/article/4/17/4124/463605/Antitumor-activity-of-the-dual-BET-and-CBP-EP300

3) Targeting BET bromodomain proteins in cancer: The example of lymphomas
Pharmacology & Therapeutics, https://www.sciencedirect.com/science/article/abs/pii/S0163725820301613?via%3Dihub
Francesco Bertoni
is currently collaborating with
Istituto Oncologico di Ricerca (IOR) (Rif. IOR)
Via Francesco Chiesa 5
6500 Bellinzona
Francesco Bertoni
on behalf of
Istituto Oncologico di Ricerca (IOR) USI (Rif. IOR)
is currently participating in the Research Group
Lymphoma Genomics
as Group Leader [Rif. 55110]
Francesco Bertoni
on behalf of
Istituto Oncologico di Ricerca (IOR) USI (Rif. IOR)
is currently Research Program Leader [Rif. 50110] for
Lymphoma and Genomics (Rif. 20000 2023)